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Abstract 
A series of new spiro[N-heterocyclic-adamantanes] was synthesized through the reaction of 
2-adamantanone with β-amino carboxamides. Depending on the chemical and physical 
characteristics of the starting compounds, the cyclocondensations proceeded under simple and 
mild (aqueous, solvent-free, ball-milling or/and microwave-assisted) conditions with no 
necessity for chromatographic purification of the products. The reaction was extended to 
leucinamide and salicylamide. 
 
Keywords: Environmentally friendly methods, aqueous, solvent-free, mechanochemical, ball-
milling reactions, microwave-assisted 
 
 
 
Introduction 
 
The adamantane cage has been successfully utilized as a stable lipophilic scaffold1 in the 
development of numerous lead compounds that demonstrate activity in the central nervous 
system.2 The 1-adamantyl group is crucial for the antiparasitic activity of 1,2,4-trioxane 
derivatives,3 and replacement of the 2-(adamantan-1-yl)acetyl group with other hydrophobic 
moieties abolished the anti-EboV activity of a new class of antiviral dipeptides.4 The 
incorporation of a spiroadamantane unit into 1,2,4-trioxanes5 and 1,2,4,5-tetraoxanes6 enhanced 
the antimalarial activity, together with low toxicity and high stability profiles both in vitro and in 
vivo. 
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Figure 1. Selected spiro[N-heterocyclic-2'-adamantane] derivatives. 
 
 In the search for new analogues of adamantine and rimantadine, a number of six-membered 
spiroadamantane rings bearing one or two nitrogens, has been prepared. The in vivo antiviral 
activity of 3-piperidine derivative A against Japanese influenza A2 was found to be 
approximately the same as that of 1-adamantanamine.7 4-Piperidine derivative B proved to 
display significant anti-influenza A (H3N2) and trypanocidal activity,8 while piperazine C 
likewise inhibited H3N2 influenza A virus replication.9 The (S)-enantiomer of acethydroxamic 
acid D was the most effective in a study of the trypanidical activities of hydroxamic acid-based 
derivatives.10 In a series of spiro[isoquinoline-3,2'-adamantanes], compound E emerged as a 
promising neurotropic candidate, and at the same time was not toxic towards normal cells.11 
 To the best of our knowledge, only the spiro[1,3-N,N-heterocyclic-adamantanes] F,12 G13 and 
H14 have been synthetized previously; moreover pharmacological investigations have not been 
performed on such spiro ring systems.  
 In the series of spirocyclic adamantanes, we have focused mainly on the synthesis of 
spiro[quinazoline-2,2'-adamantanes] through green chemistry methodology and alternative forms 
of energy input. All of the products were prepared from commercially available adamantan-2-
one (1);15 the spirocyclizations were carried out with α- and β-amino acid derivatives in the 
presence of a catalytic amount of I2.
16 
 
 
Results and Discussion 
 
We have previously described ecofriendly methods for the preparation of quinazolin-4(1H)-ones 
in aqueous17 or solvent-free medium from a 2-aminobenzamide (2a)18 or 2-amino-
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benzhydrazides (2b and 2c)19 and a number of aldehydes20 or ketones.21 Inspired by the excellent 
results of the mechanochemical synthesis (e.g., 3a, Table 1, conversion ~ 99%), we decided to 
extend the ring closure of 1 with the reactions of a number of amides and hydrazides under either 
aqueous or ball-milling conditions. 
 The idea for our initial mechanochemical experiment stemmed from the study by Oliveira et 
al.,22 in which a series of hydrazones was synthetized by the ball-milling of aldehydes with 
hydrazines in the solid state at rt. Conversions of 85–99% were obtained, depending on the 
aldehyde/hydrazide used. These observations on the mechanical solvent-free and solid-state 
procedures led us to investigate the solid–solid reactions of equimolar amounts of hydrazides 2b 
and 2c with 1, catalyzed by I2 (5 mol%) in a vibrational ball-mill. The progress of the reactions 
was monitored by TLC, and the conversions of the mechanochemical reactions were determined 
by 1H NMR. 
 
Table 1. Syntheses of spiroadamantane-2,2'-quinazolinones (3a,3b) and 2-(adamantan-2-
ylidene)hydrazide (3c) through the application of mechanical forces 
O
1
NH2
N
H
R
O
(i)(i)
2a,2b
3a,3b
2c
3c
NH2
N
H
N
O
NH2
N
H
R
O
N
H
N
O
R
 
Entry R 
Amide/Hydrazide 
equiv. 
Temp. 
[°C] 
Time 
[h] 
Product 
Yield 
[%]a 
Mp 
[°C]b 
 
1 H 2a 1 25 2 3a 
99 
(90)c 
270–274 
(281–283)21 
2 NHPh 2b23 1 25 4 3b 
95 
(91)c 
220–225 
(228–230)d 
3 NH2 2c
23 1 25 1 3c 
98 
(93)c 
231–235 
(244–246)e 
(i) 2 mmol of each reactant, 25 mg (5 mol%) of I2, in a stainless-steel jar (25 mL) with two ZrO2 
balls (15 mm) at 25 Hz; a on the basis of 1H NMR; b from aqueous suspension; c isolated yields 
from aqueous work-up (3 mL of 2% Na2S2O5 and 5 mL of water, 25 Hz for 5 min, filtration, and 
washing with 5 mL of water); d from EtOH; e from MeOH–Et2O. 
 
 After grinding for 4 h, the 1H NMR spectrum revealed that the conversion of 1 and 2b to 
quinazoline 3b was almost complete (95%). The use of ZrO2 balls insteated of stainless-steel 
balls was essential in order to avoid the paramagnetic impurity effects in the NMR determination 
of the conversions of the crude products in our further mechanochemical studies.21,24 When it 
was necessary to eliminate I2 from the crude products 3a–3i, a simple aqueous work-up 
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technique was applied (Tables 1 and 2c). Analytically pure samples of ball-milled 3a–3i were 
prepared by crystallization from a suitable solvent. 
 For a comparison of the reactivities of 2b and 2c, the mixture of 1 and 2c were mixed in the 
presence of iodine at 25 Hz for 1 h. NMR analysis demonstrated the presence of hydrazone 3c in 
a conversion of 98%. The rearrangement of 3c to the thermodynamically favored 
quinazolinone17 was not observed on heating at reflux hydrazone 3c in EtOH or in water, or on 
the application of microwave (MW) irradiation in the same solvents at 160 °C either without a 
catalyst or in the presence of I2 or p-TSA as catalyst. It is presumed that rearrangement through 
the transimination of 3c did not occur because of the steric hindrance of the adamantane moiety. 
On the other hand, the presence of the phenyl substituent on the benzhydrazide component led to 
regioselective ring closure of 1 with 2b.25 
 Since (cyclo)aliphatic amines are usually good nucleophiles, we extended the ball-milling 
methodology to the spirocyclizations of β-aminoamides 2d–2h with 1. First, a mixture of 1 and 
2d was milled at 25 Hz for 1 h in the absence of the I2 catalyst. The
.1H NMR spectrum of the 
reaction mixture showed that product 3d was obtained in a yield of 8–10% [Figure 2 (I)]. When 
5 mol% of solid I2 was added to the mixture and the mechanical treatment was continued for an 
additional 1 h under the same conditions, crude 3d was formed with a conversion of 85% (Figure 
2 II). The results shown in Figure 2 can be explained by the fact that I2 promotes activation of the 
imine (Schiff base) in the intramolecular cyclization.26 
 
 
Figure 2. 1H NMR spectra of (I) a catalyst-free reaction mixture of 2d and 1 after ball-milling 
for 1 h, (II) the reaction mixture after the addition of 5 mol% I2 followed by mechanochemical 
treatment for 1 h, and (III) the mixture of I2, 1 and 2d after milling for 2 h. 
 
 
General Papers  ARKIVOC 2015 (vii) 158-171 
 Page 162 ©ARKAT-USA, Inc. 
Table 2. Syntheses of 2-spiroquinazolinones (3d–3h) and 2-spiroimidazolidine (3i) in a 
vibrational ball-mill 
ONH2
NH2
O
1
Me
Me
3d−3h
2d−2h2i
3i
(i)(i)
NH
N
HMe
Me
O
NH
N
H
XQ
O
NH2
NH2
XQ
O
 
Entry Config. X Q 
Amide 
equiv. 
Temp. 
[°C] 
Time 
[h] 
Product 
Yield 
[%]a 
Mp 
[°C]b 
 
1 diexo        CH2     –CH=CH– 2d
28 1 25 2 
NH
N
H
O
 
3d 
99 
(95)c 
210–213 
(221–222)d 
2 diexo         O       –CH=CH– 2e29 1 25 3 
NH
N
H
O
O
 
3e 
97 
(93)c 
185–190 
(190–192)d 
3 diendo      CH2     –CH=CH– 2f
28 1 25 3 
NH
N
H
O
 
3f 
98 
(94)c 
207–210 
(211–212)d 
4 cis            —        –CH2CH2– 2g
30 1 25 2 
NH
N
H
O
 
3g 
99 
(91)c 
204–208 
(208–210)d 
5 trans       —        –CH2CH2– 2h30 1 25 6 
NH
N
H
O
 
3h 
87 
(65) 
243–246 
(252–254)e 
6 
 
2i31 1 25 4 
NH
N
HMe
Me
O
 
3i 
 
99 
(88)c 
206–210 
(215–216)f 
(i) 2 mmol of reactants, 25 mg (5 mol%) of I2, stainless-steel jar (25 mL) with two ZrO2 balls 
(15 mm) at 25 Hz; a on the basis of 1H NMR; b from aqueous suspension; c isolated yields from 
aqueous work-up (2 mL of 2% Na2S2O5 and 3 mL of water, 25 Hz for 5 min, filtration, and 
washing with 3 mL of water); d from EtOAc; e from EtOH; f from i-Pr2O. 
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 Encouraged by this result, we investigated the reactions of 1 with alicyclic amides 2e−2h and 
α-amino acid derivative 2i under the application of mechanical forces (entries 2−5). The 
reactions were complete in 2−4 h at 25 Hz, leading to powdery products; a liquid phase27 was not 
observed. Surprisingly, under such reaction conditions the N-methylamide derivatives 2a, 2d and 
2e did not give spirocyclic products. During the ball-milling procedure, melt mixtures were seen; 
perhaps because of the steric effects of the methyl group, mainly imine formation occurred. 
 In the light of our work on spirocyclization in/on water17–19 and reported aqueous protocols 
for the synthesis of nitrogen heterocycles by several research groups,32–34 we were motivated to 
attempt the preparation of 3a–3h in aqueous medium. For the condensation reactions followed 
by intramolecular cyclizations, an I2/KI catalyst was used.
21,26 
 We first re-examined the reaction of 1 with 2a, after the addition of 1 mol% (0.5 mL of 1% 
aqueous solution) of I2/KI
35 to a stirred suspension of stoichiometric amounts (2 mmol) of 1 and 
2a in water (10 mL). After stirring for 24 h at rt, 3a was filtered off in a yield of 86%. The 
spectroscopic data and the mp of 3a corresponded well with the literature values.21 
 
Table 3. Synthesis of adamantane derivatives 3a–3i in aqueous media (ii) 
Entry 
Amide/Hydrazide 
equiv. 
Temp. 
[°C] 
Time 
[h] 
Product 
Yield 
[%]a 
 
Mp 
[°C]b 
 
1 
2a 1 25 24 NH
NH
O
 
3a 
86 271–273 
2 2b 1 25 24 NH
N
O H
N
 
3b 
79 222–225 
3 2c 1 25 24 NH2
N
H
N
O
 
3c 
82 231–233 
4 2d 1 25 24 
NH
N
H
O
 
3d 
76 218–220 
5 2e 1 25 24 
NH
N
H
O
O
 
3e 
73 187–190 
6 2f 1 25 24 
NH
N
H
O
 
3f 
68 207–209 
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Table 3 (continued) 
Entry 
Amide/Hydrazide 
equiv. 
Temp. 
[°C] 
Time 
[h] 
Product 
Yield 
[%]a 
 
Mp 
[°C]b 
 
7 
2g 1 25 24 
NH
N
H
O
 
3g 
80 206–208 
8 2h 1 25 24 
NH
N
H
O
 
3h 
in 
traces 
– 
8 2i 1 25 72 
NH
N
HMe
Me
O
 
3i 
51 212–213 
(ii) A mixture of 2 mmol of each of the reactants and 0.5 mL of 1% I2/KI solution was stirred in 
10 mL (3a–3c) or in 3 mL (3d–3i) of water for 24 h at rt. The precipitates were filtered off, 
washed with 3 mL of water, and dried; a isolated yields from aqueous suspension; b melting 
points of filtered and dried products. 
 
 We further employed this ecofriendly protocol for the preparation of 3b and 3c (Table 3, 
entries 1–3). It is important to note that condensations of 1 with the more water-soluble 
(cyclo)alkyl amides 2d–2h were carried out in 3 mL of water (Entries 4–8). The moderate yield 
and longer reaction time of 3i can be explained by the higher solubilities of 2i and 3i in water. 
The 1H NMR data on the crude products isolated from aqueous media corresponded well with 
those on the analytically pure samples of 3a–3i.  
 To examine the mechanochemical and in/on water reaction limitations and the scope of the 
cyclizations of 1 with different amides, we applied 2-aminonicotinamide (2j),36 salicylamide 
(2k) and 5-amino-1-phenylpyrazole-4-carboxamide (2l)37 to attempt to produce 
spiroadamantane-heterocycles. We found that ball-milling or treatment in water did not lead to 
I2-catalyzed ring closure: no desired compound was isolated. In a series of further experiments, 
pyrido[2,3-d]pyrimidine 3j and pyrazolo[3,4-d]pyrimidine 3l were prepared under MW 
irradiation, while benz[1,3]oxazine 3k separated out from a refluxed solution in EtOH (Table 4). 
 Heterocycle 3j was synthesized in an analogous manner to spiro[cyclohexane-1,2'-
pyrido[2,3-d]pyrimidine]38 through the use of MW irradiation. When a mixture of 1 and 2j with 
1 mol% of I2 was irradiated (100 W) in a sealed vial, 3j was obtained in good yield with 
excellent purity (Entry 1). Melzig reported the synthesis of photochromic 3k when a reaction 
mixture of 1, 2k and polyphosphate ethyl ester was refluxed in CHCl3. The pale-yellow 
crystalline product melted at 220–225 °C,39 but its IR and NMR data were not published. In view 
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of the lack of a spectroscopic analysis, we decided to attempt to prepare 3k by a greener 
procedure. An equimolar ratio of 1 and 2k with 1 mol% of I2 was refluxed in EtOH under 
conventional heating for 8 h. Water was added to the cooled solution, and 3k separated out as a 
colourless precipitate in a yield of 71%. 
 
Table 4. Synthesis of adamantane derivatives 3j–3l in EtOH (iii) or in DCM (iv) 
 
O
1
(iii)
3j: Y = N, Z =NH
3k: Y = CH, Z = O
2j,2k
N
N NH2
O
NH2
(iv)
2l
3l
NH
N
H
N
N
O
Y
NH
ZY
O
ZH
NH2
O
 
Entry Solvent Catalyst 
Amide/ 
equiv. 
Temp. 
[°C] 
Time 
[h] 
Product 
Yield 
[%]a 
Mp 
[°C] 
1 EtOH I2 2j 1 
160 
(MW) 
6 3j 67 
(299–302)b 
303–304c 
2 EtOH I2 2k 1 
78 
(reflux) 
8 3k 71 
(279–282)b 
281–283d 
3 DCM AlCl3 2l 1.3 
110 
(MW) 
2 3l 81 221–223c 
(iii) A mixture of 2 mmol of each of the reactants, and 5 mg (1 mol%) of I2 was irradiated or 
refluxed in EtOH; (iv) a mixture of 1.5 mmol of 1, 2l and AlCl3 (2 mmol), MW in DCM; 
a 
isolated yield of crude products; b mp-s from EtOH–H2O; 
c from EtOAc; d from EtOH. 
 
 For a route to the preparation of biologically and pharmaceutically important pyrazolo[3,4-
d]pyrimidines40 with avoidance of the formation of a pyrazolopyridine, we used 2l rather than o-
aminopyrazolcarbonitrile.41 Methods (i) and (ii) led to insufficient yields, and we catalyzed the 
MW-induced reaction of 1 with 2l with various Lewis acids and solvents. We found that 
1.3 equiv. of AlCl3 in DCM was the best of the traditional Lewis acids. When the reaction was 
carried out at 110 °C (60 W) for 2 h, crude 3l was isolated in a yield of 81%. 
     In conclusion, various conditions have been examined for the condensation of 
2-adamantanone with hydrazides or amides 2a–2l, including solvent-free ball-milling, in/on 
water or in EtOH solution, and MW irradiation in EtOH solution or in DCM. The relative 
reactivities, solubilities in water and melting points of the nucleophiles all influenced the above 
protocols. These methods have a number of advantages over other methods: the reaction 
techniques are very simple, and the syntheses proceed under mild reaction conditions without the 
need for costly catalysts and chromatographic purification. 
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Experimental Section 
 
General. The reaction courses and the purities of products were monitored by TLC. 1H NMR 
spectra of the dried crude mixtures were recorded in DMSO-d6 or CDCl3 to confirm the 
conversion to 3a–3i. Analytically pure samples of 3a–3l were prepared by crystallization and 
their 1H NMR (400 Hz) and 13C NMR (100 MHz) spectra were recorded on a Bruker Avance 
DRX 400 spectrometer with TMS as internal reference. Melting points were determined on a 
Kofler apparatus. FT-IR spectra were recorded in KBr pellets on a Perkin-Elmer 100 FT-IR 
spectrometer. Elemental analyses were carried out on a Perkin-Elmer 2400 elemental analyzer. 
The MW-promoted reactions were performed in sealed reaction vials (10 mL) through use of the 
MW reactor (CEM, Discover) cavity. The ball-milling experiments were carried out in a Retsch 
MM400 mixer mill with two ZrO2 balls 15 mm in diameter in a stainless-steel jar (25 mL) at 
25 Hz at rt. 
 
Preparation of spiroadamantanes (3a,3b and 3d–3l) and hydrazone (3c) 
A. 2b–2i (2.0 mmol), 1 (0.30 g, 2.0 mmol), 25 mg (5 mol%) of I2 and two ZrO2 balls 15 mm in 
diameter were placed in a stainless-steel jar. The vessel was vibrated at 25 Hz for the appropriate 
length of time. The reaction progress was monitored by TLC. The products were recovered as 
solids (directly from the jar) and dried. The conversions to 3b–3i were determined by 1H NMR.  
In the aqueous work-up procedure, 2 or 3 mL of 2% Na2S2O5 solution and 3 or 5 mL of water 
were added to the reaction mixture in the jar. The aqueous suspension was mixed at 25 Hz for 
5 min, filtered off, washed with water (3 or 5 mL) and dried. The isolated yields and melting 
points of crude 3b–3i were determined. Analytically pure samples of compounds 3b–3i were 
recrystallized from a suitable solvent. 
B. To a stirred mixture of 1 (0.30 g, 2.0 mmol) in 0.5 mL of 1% I2/KI (1 g of I2 and 1.6 g of KI in 
100 mL of water) and 3–10 mL of water in a round-bottomed flask (25 mL), 2a–2c (2 mmol) 
was added in portions. The flask was sealed with a Teflon cap. After vigorous stirring at rt for 
24 h, 3a–3i precipitated. The product was filtered off, washed with water (3 mL) and dried. The 
purities of 3a–3i were established by 1H NMR measurements. 
C. A stirred mixture of 5 mg (1 mol%) of I2, 2k (0.27 g, 2 mmol) and 1 (0.30 g, 2 mmol) in 
EtOH (5 mL) was refluxed for 8 h. To the cooled mixture, 5 mL of water was added. The solid 
product was separated by filtration and dried. For 3j, I2 (5 mg, 1 mol%), 2j (0.28 g, 2 mmol) and 
1 (0.30 g, 2 mmol) were placed in a MW test-tube (10 mL) (which was subsequently sealed with 
a Teflon cap) which contained a magnetic stirrer and EtOH (2 mL). The test-tube was placed in 
the CEM Discover MW reactor. The solution was irradiated for 6 h at 160 °C (100 W). To the 
cooled solution, water (4 mL) was added, and the precipitated product was filtered off and dried. 
The melting points of both the crude and the recrystallized 3j and 3k were determined. 
D. 0.30 g (1.5 mmol) of 2l, 0.23 g (1.5 mmol) of 1 and 0.26 g (2 mmol) of AlCl3 were placed in a 
MW test-tube (10 mL) (sealed with a Teflon cap) containing a magnetic stirrer and 2 mL of 
DCM. The test-tube was placed in the MW reactor (CEM, Discover) cavity, microwaved at 
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110 °C (60 W) for 2 h and then cooled to room temperature. The reaction mixture was poured 
onto water (50 mL) and extracted with DCM (3 × 10 mL), and the extract was evaporated in 
vacuo. The residue was recrystallized from EtOAc. 
Analytical and spectroscopic data on 3b–3l are given below. 
3'-(Phenylamino)-1'H-spiro[tricyclo[3.3.1.13,7]decane-2,2′(1′H)-quinazolin]-4′(3′H)-one 
(3b). Beige crystals, mp 228–230 °C (EtOH); IR (cm−1): 3428, 3357, 3266, 3034, 2915, 2855, 
1623, 1615, 1496, 1481, 761, 750. 1H NMR δ (DMSO-d6, ppm): 1.35−2.18 (m, 12H, adamantyl), 
2.28 (s, 1H, adamantyl), 3.09 (d, J 12.7 Hz, 1H, adamantyl), 6.65 (t, J 7.3 Hz, 1H, ArH), 6.73–
6.81 (m, 3H, ArH), 6.86 (br s, 1H, NH), 7.08 (t, 1H, ArH), 7.20 (d, J 8.0 Hz, 1H, ArH), 7.35 (m, 
1H, ArH), 7.59 (d, J 7.6 Hz, 1H, ArH), 8.31 (br s, 1H, NH); 13C NMR δ (DMSO-d6, ppm): δ 
26.9 27.3, 32.1, 34.1, 34.5 (2×C), 34.8, 36.0, 38.7, 78.3, 113.0 (2×C), 116.8, 118.4, 118.5, 119.2, 
128.1, 129.6 (2×C), 134.1, 146.2, 150.7, 164.0; Anal. calcd. for C23H25N3O (359.46) (%): C, 76.85; 
H, 7.01; N, 11.69. Found: C, 76.65; H, 7.11; N, 11.55. 
2-Amino-N'-tricyclo[3.3.1.13,7]decanylidenebenzohydrazide (3c). Colourless crystals, mp 
244–246 °C (MeOH–Et2O); IR (cm
−1): 3484, 3358, 3210, 2910, 2899, 2849, 1646, 1636, 1584, 
1530, 1489, 1447, 751. 1H NMR δ (DMSO-d6, ppm): 1.74−2.08 (m, 12H, adamantyl), 2.60 (s, 
1H, adamantyl), 3.21 (s, 1H, adamantyl), 6.17 (br s, 2H, NH2), 6.52 (t, J 7.5 Hz, 1H, ArH), 6.70 
(d, J 8.1 Hz, 1H, ArH), 7.14 (m, 1H, ArH), 7.43 (d, J 8.0 Hz, 1H, ArH), 10.34 (br s, 1H, CONH); 
13C NMR δ (DMSO-d6, ppm): δ 28.1 (2×C), 32.6, 36.8, 38.1 (2×C), 39.4 (2×C), 40.0, 115.5 
(2×C), 117.0 (2×C), 129.6, 132.4, 150.2, 168.2 (HMQC, HMBC); Anal. calcd. for C17H21N3O 
(283.37) (%): C, 72.06; H, 7.47; N, 14.83. Found: C, 72.15; H, 7.29; N, 14.59. 
diexo-5',8'-Methano-4a',5',8',8a'-tetrahydro-1'H-spiro[tricyclo[3.3.1.13,7]decane-2,2'-
quinazolin]-4'(3'H)-one (3d). Colourless crystals, mp 221–222 °C (EtOAc); IR (cm−1): 3291, 
3056, 2899, 2844, 1635, 711 (diexo).42 1H NMR δ (DMSO-d6, ppm): 1.24 (d, J 9.0 Hz, 1H, 9'-
H), 1.43−1.80 (m, 11H, adamantyl and 9'-H), 1.82 (d, J 7.3 Hz, 1H, 4a'-H), 1.86–2.38 (m, 5H, 
adamantyl and 1'-NH), 2.69 (s, 1H, 8'-H), 3.00 (t, J 8.0 Hz, 1H, 8a'-H), 3.25 (s, 1H, 5'-H), 6.16 
(dd, J 3.1 Hz, J 5.5 Hz, 1H, 7'-H), 6.23 (dd, J 2.9 Hz, J 5.5 Hz, 1H, 6'-H), 7.79 (s, 1H, CONH); 
13C NMR (DMSO-d6, 100 MHz, ppm): δ 27.3 27.4, 32.7, 33.4, 33.7, 33.9, 35.7, 37.4, 38.6, 42.8, 
44.7, 45.4, 48.0, 52.8, 72.5, 136.7, 138.6, 172.3; Anal. calcd. for C18H24N2O (284.40) (%): C, 76.02; 
H, 8.51; N, 9.85. Found: C, 76.15; H, 8.39; N, 9.59. 
diexo-5',8'-Epoxy-4a',5',8',8a'-tetrahydro-1'H-spiro[tricyclo[3.3.1.13,7]decane-2,2'-
quinazolin]-4'(3'H)-one (3e). Colourless crystals, mp 190–192 °C (EtOAc); IR (cm−1): 3268, 
3221, 3044, 3025, 2990, 2943, 2909, 2866, 1642, 872, 707 (diexo). 1H NMR δ (DMSO-d6, ppm): 
1.40−2.43 (m, 16H, adamantyl, 4a'-H and 1'-NH), 3.18 (dd, J 6,8 Hz, J 11,2 Hz, 1H, 8a'-H), 4.72 
(s, 1 H, 8'-H), 5.20 (s, 1H, 5'-H), 6.42 (d, J 5,6 Hz, 1H, 7'-H), 6.54 (d, J 5,6 Hz, 1H, 6'-H), 8.02 
(s, 1H, CONH); 13C NMR (DMSO-d6, ppm): δ 27.3, 27.4, 32.6, 33.2, 33.7, 33.9, 36.0, 37.7, 38.5, 
42.3, 52.2, 72.7, 81.8, 83.3, 135.1, 138.1, 170.8; Anal. calcd. for C17H22N2O2 (286.37) (%): C, 
71.30; H, 7.74; N, 9.78. Found: C, 71.15; H, 7.95; N, 9.58. 
diendo-5',8'-Methano-4a',5',8',8a'-tetrahydro-1'H-spiro[tricyclo[3.3.1.13,7]decane-2,2'-
quinazolin]-4'(3'H)-one (3f). Colourless crystals, mp 207–210 °C (EtOAc); IR (cm−1): 3291, 
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3056, 2916, 2903, 2866, 1640, 872, 754 (diendo). 1H NMR δ (DMSO-d6, ppm): 0.56 (d, J 
11.8 Hz, 1H, 1'-NH), 1.31−2.40 (m, 17H, adamantyl, 4a'-H and 9'-H), 2.97 (s, 1H, 8'-H), 3.17 (s, 
1H, 5'-H), 3.74 (m, 1H, 8a'-H), 6.14 (dd, J 2.8 Hz, J 5.6 Hz, 1H, 7'-H), 6.22 (dd, J 2.8 Hz, J 
5.5 Hz, 1H, 6'-H), 7.67 (s, 1H, CONH); 13C NMR (DMSO-d6, ppm): δ 27.3 27.4, 32.6, 33.2, 
33.7, 34.0, 36.8, 37.9, 38.5, 43.2, 46.3, 46.7, 47.4, 54.1, 73.4, 134.0, 140.0, 172.2; Anal. calcd. for 
C18H24N2O (284.40) (%): C, 76.02; H, 8.51; N, 9.85. Found: C, 75.85; H, 8.58; N, 9.69. 
cis-Hexahydro-1'H-spiro[tricyclo[3.3.1.13,7]decane-2,2'-quinazolin]-4'(3'H)-one (3g). 
Colourless crystals, mp 208–210 °C (EtOAc); IR (cm−1): 3213, 2906, 1642, 1457, 1101, 807, 
775. 1H NMR δ (DMSO-d6, ppm): 1.08−2.37 (m, 25H, adamantyl, cyclohexyl and 1'-NH), 
7.43(s, 1H, CONH); 13C NMR (DMSO-d6, 100 MHz, ppm): δ 20.5, 25.5, 25.8, 27.3, 27.7, 30.7, 
32.5, 32.7, 34.1, 34.5, 36.8, 38.8, 39.8, 42.9, 44.4, 72.4, 174.2;Anal. calcd. for C17H26N2O (274.40) 
(%): C, 74.41; H, 9.55; N, 10.21. Found: C, 74.65; H, 9.58; N, 9.99. 
trans-Hexahydro-1'H-spiro[tricyclo[3.3.1.13,7]decane-2,2'-quinazolin]-4'(3'H)-one (3h). 
Colourless crystals, mp 252–254 °C (EtOAc); IR (cm−1): 3224, 2931, 2906, 2847, 1637, 1435, 
814. 1H NMR δ (CDCl3, ppm): 0.85−2.41 (m, 24H, adamantyl, cyclohexyl and 1'-NH), 2.63 (m, 
1H, cyclohexyl) 6.55(s, 1H, CONH); 13C NMR (CDCl3, ppm): δ 26.0 (2×C), 26.3, 27.2, 27.5, 
33.2, 33.6, 33.7, 34.1, 34.2, 37.2, 38.4, 40.8, 49.1, 51.4, 72.7, 173.2;  Anal. calcd. for C17H26N2O 
(274.40) (%): C, 74.41; H, 9.55; N, 10.21. Found: C, 74.45; H, 9.75; N, 10.19. 
(5'S)-5'-Isobutylspiro[tricyclo[3.3.1.13,7]decane-2,2'-imidazolidin]-4'-one (3i). 
[α]D25 –10.8 ° (EtOH, c 0.535). Colourless crystals, mp 215–216 °C (i-Pr2O); IR (cm
−1): 3197, 
3074, 2910, 2867, 1693, 1460, 880, 825, 778. 1H NMR δ (DMSO-d6, ppm) 0.82–0.96 (m, 6H, 
2×CH3), 1.22 (m, 1H, isobutyl), 1.43−2.16 (m, 17H, adamantyl, isobutyl, 1'-NH), 2.57, (m, 1H, 
5'-H), 8.68 (s, 1H, CONH); 13C NMR (DMSO-d6, ppm): δ 22.6, 24.2, 25.7, 26.9, 27.2, 33.9 
(2×C), 34.1, 34.5, 38.1, 38.7, 40.8, 43.2, 57.0, 77.9, 178.1; Anal. calcd. for C16H26N2O (262.39) 
(%): C, 73.24; H, 9.99; N, 10.68. Found: C, 73.45; H, 9.74; N, 10.49. 
1'H-Spiro[tricyclo[3.3.1.13,7]decane-2,2'-pyrido[2,3-d]pyrimidin]-4'(3'H)-one (3j).  
Colourless crystals, mp 303–304 °C (EtOAc); IR (cm−1): 3402, 3233, 2925, 2894, 1660, 1600, 
1446, 1257, 769. 1H NMR δ (DMSO-d6, ppm): δ 1.49−2.30 (m, 14H, adamantyl), 6.74 (m, 1H, 
ArH), 7.30 (br s, 1H, ArNH), 7.91 (m, 1H, ArH), 8.07 (br s, 1H, NHCO), 8.20 (m, 1H, ArH); 
13C NMR (DMSO-d6, ppm): δ 26.7 26.9, 32.6 (2×C), 33.1 (2×C), 37.3 (2×C), 38.5, 72.1, 110.6, 
114.7, 136.4 (2×C), 153.6, 157.5; Anal. calcd. for C16H19N3O (269.34) (%): C, 71.35; H, 7.11; N, 
15.60. Found: C, 71.45; H, 7.24; N, 15.49. 
Spiro[tricyclo[3.3.1.13,7]decane-2,2'-pyrido[3,2-e][1,3]oxazin]-4'(3'H)-one (3k).  
Colourless crystals, mp 281–283 °C (EtOH); IR (cm−1): 3221, 3086, 2931, 2920, 2888, 1669, 
1468, 1383, 999, 756. 1H NMR δ (DMSO-d6, ppm): 1.47−2.18 (m, 14H, adamantyl), 6.96–7.13 
(m, 2H, ArH), 7.52 (m, 1H, ArH), 7.74 (m, 1H, ArH), 8.66 (s, 1H, NHCO); 13C NMR (DMSO-
d6, ppm): δ 26.7 26.9, 33.0 (2×C), 33.5 (2×C), 36.3 (2×C), 37.8, 91.4, 117.9, 119.5, 122.6, 127.9, 
135.2, 155.5, 162.2; Anal. calcd. for C17H19NO2 (269.34) (%): C, 75.81; H, 7.11; N, 5.20. Found: C, 
75.65; H, 7.23; N, 5.09. 
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1'-Phenyl-5',7'-dihydrospiro[tricyclo[3.3.1.13,7]decane-2,6'-pyrazolo[3,4-d]pyrimidin]-
4'(1'H)-one (3l). Colourless crystals, mp 221–223 °C (EtOAc); IR (cm−1): 3238, 3079, 2923, 
2901, 2887, 1663, 1596, 1560, 1508, 871, 777, 756. 1H NMR δ (DMSO-d6, ppm): 1.50−2.23 (m, 
14H, adamantyl), 6.42 (s, 1H, NH), 7.30–7.33 (m, 2H, ArH and NHCO), 7.55 (m, 2H, ArH), 
7.77–7.89 (m, 3H, ArH and pyrazolyl), 13C NMR (DMSO-d6, ppm): δ 27.1 (2×C), 32.8 (2×C), 
34.1 (2×C), 35.8 (2×C), 38.4, 74.5, 104.9, 121.6 (2×C),127.4, 130.2 (2×C), 138.6, 139.5, 148.5, 
161.9; Anal. calcd. for C20H22N4O (334.41) (%): C, 71.83; H, 6.63; N, 16.75. Found: C, 71.85; H, 
6.83; N, 16.89. 
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